Patents Issued in March 28, 2017
  • Antibodies recognizing alpha-synuclein
    Patent number: 9605056
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 28, 2017
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Endotrophin neutralization and use thereof
    Patent number: 9605057
    Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: March 28, 2017
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Philipp Erich Scherer, Jiyoung Park, Zhiqiang An
  • Antibodies against the CXC-ELR family of chemokines
    Patent number: 9605058
    Abstract: The invention relates to antibodies which treat diseases in which human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2, and/or ENA-78 are implicated.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: March 28, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Alexander Harrison Taylor, John Richard White, Yu Xu
  • Human anti-tau antibodies
    Patent number: 9605059
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: March 28, 2017
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
  • Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms
    Patent number: 9605060
    Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: March 28, 2017
    Assignee: BIO-RAD LABORATORIES, INC.
    Inventors: Roger Walker, Benedicte Jardin
  • Antibodies with modified isoelectric points
    Patent number: 9605061
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 28, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Matthew J. Bernett
  • Polynucleotides encoding ZCYTOR17 ligand antibodies
    Patent number: 9605062
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: March 28, 2017
    Assignee: ZYMOGENETICS INC
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
  • Antigen binding proteins to Oncostatin M (OSM)
    Patent number: 9605063
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • Methods and compositions for treatment of skin disorders
    Patent number: 9605064
    Abstract: The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF? activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF? antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF? activity, such as psoriasis.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: March 28, 2017
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Martin M. Okun, Rebecca S. Hoffman, Jonathan Barker
  • Anti-IL13 antibodies and uses thereof
    Patent number: 9605065
    Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: March 28, 2017
    Assignee: GENENTECH, INC.
    Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
  • Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
    Patent number: 9605066
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: March 28, 2017
    Assignee: BIOTEST AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
  • Nucleic acids encoding anti-IL-12 antibody
    Patent number: 9605067
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: March 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Determining feline proBNP
    Patent number: 9605068
    Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof for the diagnosis of heart disease, comprising the steps of providing a feline or canine sample, contacting the sample with at least one species-specific antibody for binding to at least one epitope of the respective species proBNP, determining the concentration of at least one fragment of proBNP, and diagnosing the animal with heart disease if the concentration is elevated compared to healthy subjects.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: March 28, 2017
    Assignee: THE ANTIBODY LAB GMBH
    Inventors: Wolfgang Woloszczuk, Gerhard Hawa
  • Antibodies against the RGM a protein and uses thereof
    Patent number: 9605069
    Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: March 28, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
  • Antibody molecules to TIM-3 and uses thereof
    Patent number: 9605070
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: March 28, 2017
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Anti-CD19 antibodies
    Patent number: 9605071
    Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser9lPhe substitution in the hA19 VH sequence.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: March 28, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
  • Nucleic acids that encode interleukin-6 receptor binding polypeptides
    Patent number: 9605072
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise the amino acid sequences, nucleic acids that encode the amino acid sequences, compounds or constructs, pharmaceutical compositions comprising the amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: March 28, 2017
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • Modulation of activity of neurotrophins
    Patent number: 9605073
    Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: March 28, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Anders Nykjaer, Claus Munck Petersen
  • Multifunctional nanobodies for treating cancer
    Patent number: 9605074
    Abstract: The technology described herein is directed to methods and compositions directed to the treatment of cancer, e.g. using multifunctional receptor targeted cancer therapeutics.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 28, 2017
    Assignee: The General Hospital Corporation
    Inventor: Khalid Shah
  • Hybridoma cell line G250 and its use for producing monoclonal antibodies
    Patent number: 9605075
    Abstract: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: March 28, 2017
    Assignee: WILEX AG
    Inventors: Egbert Oosterwijk, Sven Warnaar, Stefan Ullrich
  • Methods of manipulating phagocytosis mediated by CD47
    Patent number: 9605076
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: March 28, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 9605077
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: March 28, 2017
    Assignee: Precision Biologics, Inc.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Pictet-Spengler ligation for protein chemical modification
    Patent number: 9605078
    Abstract: Aldehyde- and ketone-functionalized proteins are promising new substrates for the development of chemically modified biotherapeutics and protein-based materials. Their reactive carbonyl groups are typically conjugated with a-effect nucleophiles, such as substituted hydrazines and alkoxyamines, to generate hydrazones and oximes, respectively. However, the resulting C?N linkages are susceptible to hydrolysis under physiologically relevant conditions, which limits their utility in biological systems. Here we introduce a Pictet-Spengler ligation that is based on the classic Pictet-Spengler reaction of aldehydes and tryptamine nucleophiles. The ligation exploits the bioorthogonal reaction of aldehydes and alkoxyamines to form an intermediate oxyiminium ion; this intermediate undergoes intramolecular C—C bond formation with an indole nucleophile to form an oxacarboline product that is hydrolytically stable.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: March 28, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Carolyn Bertozzi, Paresh Agarwal, Ellen M. Sletten
  • Proteins that bind PI16 and uses thereof
    Patent number: 9605079
    Abstract: The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: March 28, 2017
    Assignee: MEDVET SCIENCE PTY LTD.
    Inventors: Simon Barry, Doreen Krumbiegel, Nicola Ga-Ling Eastaff-Leung, Ian Cameron Nicholson, Heddy Zola
  • Antibodies against CD73
    Patent number: 9605080
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: March 28, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
  • Polynucleotides encoding anti-kit antibodies
    Patent number: 9605081
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 28, 2017
    Assignee: CELLDEX THERAPEUTICS, INC.
    Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9605082
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 28, 2017
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • JAML specific binding agents, antibodies, and uses related thereto
    Patent number: 9605083
    Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 28, 2017
    Assignee: Emory University
    Inventors: Charles A. Parkos, Dominique A. Weber
  • Heterodimeric proteins
    Patent number: 9605084
    Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: March 28, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, John Desjarlais
  • Biomass treatment for hydrothermal hydrocatalytic conversion
    Patent number: 9605085
    Abstract: A selective removal of metal and its anion species that are detrimental to subsequent hydrothermal hydrocatalytic conversion from the biomass feed prior to carrying out catalytic hydrogenation/hydrogenolysis/hydrodeoxygenation of the biomass in a manner that does not reduce the effectiveness of the hydrothermal hydrocatalytic treatment while minimizing the amount of water used in the process is provided.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 28, 2017
    Assignee: SHELL OIL COMPANY
    Inventors: Juben Nemchand Chheda, Joseph Broun Powell
  • Resin composition and resin molded article
    Patent number: 9605086
    Abstract: A resin composition includes a cellulose derivative, wherein a saturated water absorption of the resin composition is in a range of 7% or greater.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: March 28, 2017
    Assignee: FUJI XEROX CO., LTD.
    Inventor: Kenji Yao
  • Process for making a modified starch product
    Patent number: 9605087
    Abstract: A process for modifying starch is described. The process can be used as an alternative to conventional starch modification processes, such as substitution and crosslinking. The process and resulting product can reduce, substantially reduce, substantially eliminate or eliminate the sodium level typically associated with conventionally modified starch products.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: March 28, 2017
    Assignee: General Mills, Inc.
    Inventors: Ling-Hua Han, Ya-Jane Wang
  • Catalyst compositions and their use for hydrogenation of nitrile rubber
    Patent number: 9605088
    Abstract: This invention relates to novel catalyst compositions based on Ruthenium- or Osmium-based complex catalysts and to a process for selectively hydrogenating nitrile rubbers in the presence of such catalyst compositions.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 28, 2017
    Assignee: ARLANXEO Deutschland GmbH
    Inventors: Qingchun Liu, Zhenli Wei
  • Attrition resistant catalyst system for manufacture of polyolefins
    Patent number: 9605089
    Abstract: The present invention relates to regular shaped magnesium particles containing attrition resistant precursors and procatalysts thereof and processes for their synthesis and their use in the manufacture of polyolefins. More particularly, the present invention relates to a process for the synthesis of a said precursor particles which give highly active and improved surface area procatalysts for producing high bulk density polyolefin resins containing low fines and capable of incorporating high rubber content. In particular, the present invention relates to process for the synthesis of an attrition resistant precursors to prepare an attrition resistant Zeigler Natta procatalysts synthesized by using the precursors and to the polyolefin resin synthesized using the said procatalysts.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: March 28, 2017
    Assignee: RELIANCE INDUSTRIES LIMITED
    Inventors: Virendrakumar Gupta, Saurabh Singh, Jomichan Joseph, Kamlesh J. Singala, Bhavesh K. Desai
  • Activated clay for treating aromatic hydrocarbons
    Patent number: 9605090
    Abstract: An activated clay for treating aromatic hydrocarbons, containing montmorillonite in an amount of not less than 34% by mass, having an SiO2/Al2O3 mol ratio in a range of 3.8 to 8.0, and desorbing ammonia in an amount in a range of 0.11 to 0.20 mmols/g as measured by the ammonia TPD method with the heat of adsorption in a range of 128 to 148 kJ/mol. The activated clay comprises an acid-treated product of smectite clay, imposes no limitation on the area where the starting clay is produced, and features long catalytic life free of dispersion in the properties.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: March 28, 2017
    Assignee: Mizusawa Industrial Chemicals, Ltd.
    Inventors: Noriyuki Takahashi, Yasuo Saitoh
  • Separation of monomer components from light components
    Patent number: 9605091
    Abstract: Process for enhancing the separation of monomer components from light components other than monomer by providing a first stream containing monomer and light components other than monomer and passing the first stream to a first separator at a first pressure to separate a gaseous second stream containing at least some of the light components other than monomer and provide a liquid third stream containing monomer. A portion of the third stream and a fourth stream containing monomer and light components other than monomer is passed to a second separator at a second pressure which is lower than the first pressure to separate a gaseous fifth stream containing at least some of the light components other than monomer from the fourth stream and provide a liquid sixth stream containing monomer.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 28, 2017
    Assignee: INEOS EUROPE AG
    Inventors: Daniel Marissal, Philip Van Breuseghem, Brent R. Walworth
  • Polymerisation process
    Patent number: 9605092
    Abstract: Polymerization process, in particular for the polymerization of monomer selected from ethylene and propylene in a reaction system containing at least three reactors operated in series. The process includes (a) polymerizing monomer in a first reactor having a volume of at least 50 m3 to produce a first polymer, (b) passing the first polymer to a second reactor and polymerizing monomer in the second reactor to produce a second polymer containing the first polymer and polymer produced in the second reactor, and (c) passing the second polymer to a third reactor and polymerizing monomer in the third reactor to produce a third polymer containing the second polymer and polymer produced in the third reactor. The polymerizations are performed such that between 0.01 and 5 w % of the total mass of the third polymer is polymer produced in the second reactor.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: March 28, 2017
    Assignee: INEOS EUROPE AG
    Inventors: Marc Jean-Marie Ghislain Parisel, Philip Van Breuseghem, Brent R. Walworth
  • Biaxially stretched polypropylene film for capacitors
    Patent number: 9605093
    Abstract: A biaxially stretched polypropylene film for a capacitor containing an isotactic polypropylene. The weight average molecular weight (Mw) of the isotactic polypropylene as measured by gel permeation chromatography (GPC) is 250,000 to 450,000, the molecular weight distribution Mw/Mn is 7 to 12 and Mz/Mn is 20 to 40, and the value of a difference obtained by subtracting a differential distribution value when the logarithmic molecular weight Log(M)=6 from a differential distribution value when Log(M)=4.5 on a molecular weight distribution curve thereof is 8% to 20%. The ultrathin biaxially stretched polypropylene film for a capacitor has superior heat resistance performance and withstands voltage performance.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: March 28, 2017
    Assignee: OJI HOLDINGS CORPORATION
    Inventors: Tadakazu Ishiwata, Yuichi Shishido
  • Method for producing water absorbent resin particles
    Patent number: 9605094
    Abstract: There is disclosed a method for producing water-absorbent resin particles, comprising a polymerization step that includes mixing an oily liquid comprising a hydrocarbon dispersing medium and a surfactant, and an aqueous liquid comprising an aqueous solvent and a water-soluble ethylenically unsaturated monomer, forming a suspension comprising an oily liquid and an aqueous liquid dispersed in the oily liquid, and polymerizing the water-soluble ethylenically unsaturated monomer in the suspension. The HLB of the surfactant is 6 or greater, and the temperature of the suspension is kept at 35° C. or higher during the period from initial mixing of the oily liquid and aqueous liquid until complete mixing of the entire amounts.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: March 28, 2017
    Assignee: Sumitomo Seika Chemicals Co., Ltd.
    Inventors: Atsushi Heguri, Kenji Tanimura, Yuichi Onoda, Masayoshi Handa
  • Polymerization product pressures in olefin polymerization
    Patent number: 9605095
    Abstract: A process for making a low density polymer in a polymerization reactor system, the process comprising polymerizing an olefin monomer, and optionally an olefin comonomer, in the presence of a diluent in a polymerization reactor to make a polymerization product slurry consisting of a liquid phase and a solid phase, wherein the solid phase comprises an olefin polymer having a density of between about 0.905 g/cm3 to about 0.945 g/cm3; and discharging the polymerization product slurry from the polymerization reactor through a continuous take-off valve to make a mixture further comprising a vapor phase. The mixture comprises a pressure less than a bubble point pressure of a component in the polymerization product slurry.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: March 28, 2017
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: John D. Hottovy, Scott E. Kufeld
  • Methods for polyolefin polymerization with high activity catalyst systems
    Patent number: 9605096
    Abstract: A method is provided for polymerizing an olefin monomer in a reactor with a highly active polyolefin polymerization catalyst system. The method includes introducing a catalyst system comprising a catalyst and a catalyst activator into the reactor containing the olefin monomer with less than 10 seconds or no pre-contacting time of the catalyst and the catalyst activator prior to introducing the catalyst and the catalyst activator into the reactor. The catalyst system may have a standard adjusted catalyst activity of greater than 10 gPgcat?1hr?1.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: March 28, 2017
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Todd S. Edwards, Kevin W. Lawson
  • Low density polyolefin resins with low molecular weight and high molecular weight components, and films made therefrom
    Patent number: 9605097
    Abstract: Disclosed herein are ethylene-based polymers produced using dual metallocene catalyst systems. These polymers have low densities, high molecular weights, and broad molecular weight distributions, as well as having the majority of the long chain branches in the lower molecular weight component of the polymer, and the majority of the short chain branches in the higher molecular weight component of the polymer. Films produced from these polymers have improved impact and puncture resistance.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: March 28, 2017
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Ashish M. Sukhadia, Max P. McDaniel, Errun Ding, Guylaine St. Jean, Qing Yang, Daniel G. Hert, Chung Ching Tso
  • Molecular weight control of polyolefins using halogenated bis-phenylphenoxy catalysts
    Patent number: 9605098
    Abstract: A process for preparing an olefin homopolymer or copolymer comprises contacting ethylene, an alpha-olefin, or a combination, and a catalytic amount of a metal-ligand complex catalyst of a particular formula that requires at least one halogen atom that is ortho to a bridging moiety. The strategic location of the halogen atom(s) ensures a product having a molecular weight that is predictably and significantly reduced in comparison with that of copolymers produced using otherwise identical metal-ligand complex catalysts that lack halogen atoms at the specified sites.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: March 28, 2017
    Assignee: Dow Global Technologies LLC
    Inventors: Jerzy Klosin, Ruth Figueroa, Robert D J Froese
  • Olefin resin
    Patent number: 9605099
    Abstract: Provided are a polyolefin resin having two crystallization temperatures, a resin composition including the polyolefin resin, an encapsulant film, a method for manufacturing the encapsulant for an optoelectronic device, and an optoelectronic device, in which the encapsulant having high light transmittance and low haze value can be provided even under the condition of low lamination, and the resin composition including the polyolefin resin can be used for manufacturing various encapsulants for an optoelectronic device, thereby providing excellent adhesive strength with the front substrate and back sheet included in the device, especially, a long-term adhesion property and improved heat resistance.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: March 28, 2017
    Assignee: LG CHEM, LTD.
    Inventors: Jin Sam Gong, Choong Hoon Lee, Sung Ho Choi, Ji Yoon Woo, Hyo Ju Kim
  • Higher density polyolefins with improved stress crack resistance
    Patent number: 9605100
    Abstract: Disclosed herein are polymerization processes for the production of olefin polymers. These polymerization processes can employ a catalyst system containing two or three metallocene components, resulting in ethylene-based copolymers that can have a medium density and improved stress crack resistance.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: March 28, 2017
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Mark L. Hlavinka, Errun Ding, Paul DesLauriers, Yongwoo Inn, Lili Cui, Qing Yang, Ashish M. Sukhadia, Guylaine St. Jean, Richard M. Buck
  • Pigment multimer, coloring composition, cured film, color filter, method for manufacturing color filter, solid-state imaging element, and image display device
    Patent number: 9605101
    Abstract: Provided is a pigment multimer whereby a pattern can be appropriately formed during formation of a pattern. Further, provided are a coloring composition using the pigment multimer; and a cured film, a color filter, a method for manufacturing a color filter, a solid-state imaging element, and an image display device, each of which uses the coloring composition. The pigment multimer (A) has a non-nucleophilic counter anion.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: March 28, 2017
    Assignee: FUJIFILM Corporation
    Inventors: Yuushi Kaneko, Tetsuya Watanabe, Suguru Samejima, Junichi Ito, Naotsugu Muro, Yoshinori Taguchi, Kazuya Oota
  • Asymmetric regio-regular conjugated polymers for electronic applications
    Patent number: 9605102
    Abstract: A polymer consisting of a regio-regular polymer backbone basing on asymmetric fluorine-substituted 2,1,3-benzothiadiazole units (FBT) having a Formula 1MP0: where. R1 is any alkyl group of 1-30 carbons; R2 is any alkyl group of 1-30 carbons; n is any number greater than 6; D is an aryl moiety.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 28, 2017
    Inventors: Steven Shuyong Xiao, Yali Yang
  • Process for producing photochromic optical material
    Patent number: 9605103
    Abstract: The process for producing photochromic optical materials of the present invention includes a step (i) of reacting at least one polymerizable monomer (A) having two or more ethylene-based unsaturated groups with at least one polythiol (B) having two or more mercapto groups to obtain a prepolymer; a step (ii) of mixing the prepolymer and a photochromic compound (C) to obtain a polymerizable composition; and a step (iii) of polymerizing the polymerizable composition, wherein, before the reaction of the step (i), the molar number of the mercapto groups included in the polythiol (B) is smaller than the molar number of the ethylene-based unsaturated groups included in the polymerizable monomer (A).
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: March 28, 2017
    Assignee: MITSUI CHEMICALS, INC.
    Inventor: Akinori Ryu
  • Antioxidant treatment of asphalt binders
    Patent number: 9605104
    Abstract: A combination of antioxidants and method of incorporating the antioxidants into an asphalt binder to make a modified asphalt binder are described. The antioxidants comprise a thioester and an aldehyde. The aldehyde and thioester, in a ratio between about 1:100 and about 100:1 parts by weight, are added to an asphalt binder. An acidic catalyst is also added in a concentration between about 0.1 wt % and about 18 wt % of the asphalt binder. The antioxidants, asphalt binder, and catalyst are mixed at a temperature between about 85° C. and about 135° C. for a time between about 30 minutes and about 6 hours. The antioxidants are capable of improving the performance grade of the asphalt binder. The modified asphalt binder possesses superior resistance to oxidative age hardening compared to other modified asphalt binder compositions that incorporate various antioxidants.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: March 28, 2017
    Assignee: The Board of Trustees of The University of Illinois
    Inventors: Alex K. Apeagyei, William G. Buttlar, Barry J. Dempsey
  • Method for producing polythiol compound, polymerizable composition for optical material, and uses thereof
    Patent number: 9605105
    Abstract: Provided is a method for producing a molded product comprising preparing a polymerizable composition for optical materials and curing the polymerizable composition for optical materials to produce the molded product. The preparation of the polymerizable composition comprises preparing a polythiol compound containing, as a main component, one kind or two or more kinds selected from a defined group of compounds, and preparing the polymerizable composition from the polythiol compound.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 28, 2017
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Masaru Kawaguchi, Takeshi Nishimura